ARTIVION, INC. — Form 10-Q
Filed August 7, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On May 17, 2026, Artivion (buyer) amended its Securities Purchase Option Agreement with Israeli private company Endospan Ltd. and Shareholder Representative Services LLC. The amendment restructures consideration allocation: $5.0M of closing cash goes solely to ordinary shareholders as of April 22, 2026 (excluding option holders); splits closing vs. deferred (additional) consideration; handles Section 280G tax waivers for change-of-control payments; extends D&O tail insurance to 7 years post-close; and clarifies payment flows through Endospan's U.S. subsidiary for U.S. person option holders. Specific dollar escrows: $16.5M indemnity escrow, $1.0M adjustment escrow, $0.1M representative reserve fund. No acquisition price stated in this amendment.
Why this rating
Amendment is procedural restructuring of prior deal terms (original agreement Sept 2019, prior amendments July 2024 & Jan 2026). No new valuation, price, or material business change disclosed. Relative to $1.4B market cap, transaction structure adjustments are routine M&A mechanics. No impact on ongoing operations or financial condition.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.